

David Bermudes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8095792/publications.pdf>

Version: 2024-02-01

38
papers

3,281
citations

304743

22
h-index

361022

35
g-index

38
all docs

38
docs citations

38
times ranked

3123
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumour-targeting bacteria engineered to fight cancer. <i>Nature Reviews Cancer</i> , 2018, 18, 727-743.	28.4	439
2	Co-Expression of a Chimeric Protease Inhibitor Secreted by a Tumor-Targeted Protects Therapeutic Proteins from Proteolytic Degradation. <i>Journal of Microbiology and Biotechnology</i> , 2018, 28, 2079-2094.	2.1	0
3	EGFR-targeted Chimeras of <i>Pseudomonas</i> ToxA released into the extracellular milieu by attenuated <i>Salmonella</i> selectively kill tumor cells. <i>Biotechnology and Bioengineering</i> , 2016, 113, 2698-2711.	3.3	16
4	Isolation and Analysis of Suppressor Mutations in Tumor-Targeted msbB <i>Salmonella</i> . <i>Methods in Molecular Biology</i> , 2016, 1409, 95-123.	0.9	3
5	Accumulation of single-stranded DNA in <i>Escherichia coli</i> carrying the colicin plasmid pColE3-CA38. <i>Plasmid</i> , 2015, 77, 7-16.	1.4	7
6	A culture-based method for determining the production of secreted protease inhibitors. <i>Journal of Microbiological Methods</i> , 2014, 100, 105-110.	1.6	10
7	Optimizing Liposomal Cisplatin Efficacy through Membrane Composition Manipulations. <i>Chemotherapy Research and Practice</i> , 2011, 2011, 1-7.	1.6	17
8	Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. <i>Leukemia Research</i> , 2010, 34, 1214-1223.	0.8	127
9	msbB deletion confers acute sensitivity to CO ₂ in <i>Salmonella enterica</i> serovar Typhimurium that can be suppressed by a loss-of-function mutation in zwf. <i>BMC Microbiology</i> , 2009, 9, 170.	3.3	12
10	In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. <i>Leukemia Research</i> , 2009, 33, 129-139.	0.8	305
11	Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations <i>in vitro</i> and <i>in vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2266-2275.	4.1	104
12	Tumor-Targeted <i>Salmonella typhimurium</i> Overexpressing Cytosine Deaminase: A Novel, Tumor-Selective Therapy. <i>Methods in Molecular Biology</i> , 2009, 542, 649-659.	0.9	23
13	Modulating the Therapeutic Activity of Nanoparticle Delivered Paclitaxel by Manipulating the Hydrophobicity of Prodrug Conjugates. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 3288-3296.	6.4	112
14	Attenuated <i>Salmonella</i> Targets Prodrug Activating Enzyme Carboxypeptidase G2 to Mouse Melanoma and Human Breast and Colon Carcinomas for Effective Suicide Gene Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 4259-4266.	7.0	78
15	PmrA(Con) Confers pmrHFIJKL-Dependent EGTA and Polymyxin Resistance on msbB <i>Salmonella</i> by Decorating Lipid A with Phosphoethanolamine. <i>Journal of Bacteriology</i> , 2007, 189, 5161-5169.	2.2	27
16	Positron emission tomography (PET) imaging of tumor-localized <i>Salmonella</i> expressing HSV1-TK. <i>Cancer Gene Therapy</i> , 2005, 12, 101-108.	4.6	78
17	Construction of VNP20009: A Novel, Genetically Stable Antibiotic-Sensitive Strain of Tumor-Targeting <i>Salmonella</i> for Parenteral Administration in Humans. , 2004, , 47-60.		31
18	Hot Spot for a Large Deletion in the 18- to 19-Centisome Region Confers a Multiple Phenotype in <i>Salmonella enterica</i> Serovar Typhimurium Strain ATCC 14028. <i>Journal of Bacteriology</i> , 2004, 186, 8516-8523.	2.2	13

#	ARTICLE	IF	CITATIONS
19	Construction of VNP20009: a novel, genetically stable antibiotic-sensitive strain of tumor-targeting Salmonella for parenteral administration in humans. <i>Methods in Molecular Medicine</i> , 2004, 90, 47-60.	0.8	49
20	Bacteria as tumour-targeting vectors. <i>Lancet Oncology</i> , The, 2003, 4, 548-556.	10.7	257
21	Tumor-Targeted Salmonella. <i>Advances in Experimental Medicine and Biology</i> , 2002, 465, 57-63.	1.6	48
22	Tumor-Targeted Salmonella Expressing Cytosine Deaminase as an Anticancer Agent. <i>Human Gene Therapy</i> , 2002, 13, 1225-1233.	2.7	107
23	Live bacteria as anticancer agents and tumor-selective protein delivery vectors. <i>Current Opinion in Drug Discovery & Development</i> , 2002, 5, 194-9.	1.9	19
24	Tumour-Selective Salmonella-Based Cancer Therapy. <i>Biotechnology and Genetic Engineering Reviews</i> , 2001, 18, 219-233.	6.2	17
25	Extragenic Suppressors of Growth Defects in <i>msbB</i> Salmonella. <i>Journal of Bacteriology</i> , 2001, 183, 5554-5561.	2.2	49
26	Biodistribution and Genetic Stability of the Novel Antitumor Agent VNP20009, a Genetically Modified Strain of <i>Salmonella typhimurium</i> . <i>Journal of Infectious Diseases</i> , 2000, 181, 1996-2002.	4.0	275
27	Tumor-Targeted Salmonella: Strain Development and Expression of the HSV-tk Effector Gene. , 2000, 35, 419-436.		3
28	Comparative Evaluation of the Acute Toxic Effects in Monkeys, Pigs and Mice of a Genetically Engineered Salmonella Strain (VNP20009) Being Developed as an Antitumor Agent. <i>International Journal of Toxicology</i> , 2000, 19, 19-25.	1.2	25
29	Use of preferentially replicating bacteria for the treatment of cancer. <i>Journal of Clinical Investigation</i> , 2000, 105, 1027-1030.	8.2	145
30	Lipid A mutant Salmonella with suppressed virulence and TNF α induction retain tumor-targeting in vivo. <i>Nature Biotechnology</i> , 1999, 17, 37-41.	17.5	382
31	Upstream elements required for expression of nucleoside triphosphate hydrolase genes of <i>Toxoplasma gondii</i> Note: Nucleotide sequences data reported in this paper are available in the GenBank $\text{\textcircled{C}}$ under the accession number U96965.1. <i>Molecular and Biochemical Parasitology</i> , 1998, 92, 229-239.	1.1	54
32	Melanoma x macrophage hybrids with enhanced metastatic potential. <i>Clinical and Experimental Metastasis</i> , 1997, 16, 299-312.	3.3	122
33	Cloning of a cDNA encoding the dense granule protein GRA3 from <i>Toxoplasma gondii</i> . <i>Molecular and Biochemical Parasitology</i> , 1994, 68, 247-257.	1.1	63
34	Kinetics and pattern of organelle exocytosis during <i>Toxoplasma gondii</i> /host-cell interaction. <i>Zeitschrift für Parasitenkunde (Berlin, Germany)</i> , 1993, 79, 402-408.	0.8	179
35	In vitro antagonism of bioluminescent fungi by <i>Trichoderma harzianum</i> . <i>Mycopathologia</i> , 1991, 115, 19-29.	3.1	10
36	Nitrogen fixation in association with Ecuadorean bromeliads. <i>Journal of Tropical Ecology</i> , 1991, 7, 531-536.	1.1	22

#	ARTICLE	IF	CITATIONS
37	Effects of Culture Conditions on Mycelial Growth and Luminescence in <i>Panellus Stypticus</i> . <i>Mycologia</i> , 1990, 82, 295-305.	1.9	19
38	Fungi in neotropical epiphyte roots. <i>BioSystems</i> , 1989, 23, 65-73.	2.0	34